| Journal | Medical cannabis and cannabinoids |
| Study Type | Randomized Trial |
| Population | Human participants |
This is the first randomized controlled trial specifically examining cannabigerol (CBG) for sleep disorders in veterans, a population with high rates of sleep disturbances and PTSD. The study provides initial safety data for CBG dosing and establishes feasibility for decentralized cannabis clinical trials.
This triple-blind, placebo-controlled trial randomized 63 veterans with sleep issues to receive oral CBG (25mg daily for 2 weeks, then 50mg daily for 2 weeks) or placebo. Primary endpoint was sleep quality measured by the Medical Outcomes Study Sleep Problems Index II, with secondary measures including quality of life (WHODAS-2.0-12), PTSD symptoms (PCL-5), and objective sleep data via Fitbit actigraphy. While the study found a favorable safety profile for CBG, efficacy results were inconclusive for sleep improvement. The decentralized design represents an innovative approach to cannabis research but may have introduced methodological challenges.
“I’m encouraged by the safety profile but not surprised by the inconclusive efficacy results given the modest sample size and relatively low CBG doses studied. This reinforces my clinical observation that minor cannabinoids like CBG require more rigorous dose-finding studies before we can make meaningful efficacy claims.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What is CBG and how does it differ from other cannabis compounds for sleep?
- Did CBG effectively improve sleep quality in this veteran population?
- What was the safety profile of CBG in this study?
- What dosing protocol was used for CBG in this trial?
- Were there any effects on PTSD symptoms or quality of life measures?
FAQ
What is CBG and how does it differ from other cannabis compounds for sleep?
Cannabigerol (CBG) is a non-psychoactive cannabinoid that differs from THC and CBD in its potential therapeutic mechanisms. This study investigated oral CBG specifically for sleep issues in veterans, using doses of 25-50mg daily in a rigorous placebo-controlled trial design.
Did CBG effectively improve sleep quality in this veteran population?
The study results were inconclusive regarding CBG’s efficacy for sleep improvement based on the primary endpoint (MOS-SS SPI-II questionnaire). While the trial was completed with 63 randomized participants, researchers stated that “no firm conclusion on the efficacy of CBG in improving sleep can be made.”
What was the safety profile of CBG in this study?
CBG demonstrated a favorable safety profile in this veteran population over the 4-week treatment period. The researchers noted that the positive safety findings support conducting future studies with CBG for sleep disorders.
What dosing protocol was used for CBG in this trial?
Participants received a stepped dosing approach: 25mg of oral CBG daily for the first 2 weeks, then increased to 50mg daily for an additional 2 weeks. This gradual dose escalation followed a 2-week run-in phase before randomization.
Were there any effects on PTSD symptoms or quality of life measures?
The study evaluated PTSD symptoms using the PCL-5 questionnaire and quality of life via the WHODAS-2.0-12 instrument as secondary endpoints. However, the provided study summary does not report specific outcomes for these measures, focusing primarily on the sleep-related findings.